

DURECT to Present at the Rodman & Renshaw Global Investment Conference

CUPERTINO, Calif., Sept. 6, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Investment Conference on Monday, September 12 at 9:35 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel in New York City. Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.

A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/rrshq26/drrx.

A live audio webcast of the presentation will also be available by accessing DURECT's homepage at www.www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a biopharmaceutical company actively developing new therapeutics based on its Epigenomic Regulator Program and proprietary drug delivery platforms. DUR?928, a new chemical entity in Phase 1 development, is the lead candidate inDURECT's Epigenomic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 plays an important regulatory role in lipid homeostasis, inflammation, and cell survival, and may have applications related to acute organ injury and chronic metabolic disease, notably nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). DURECT's advanced oral, injectable, and transdermal delivery technologies enable new indications and enhanced attributes, such as abuse deterrence, extended dosing intervals, and superior safety and efficacy, for small-molecule and biologic drugs. Late-stage development programs in this category include POSIMIR® and REMOXY® ER, addressing key unmet needs in pain management. For more information, please visit www.www.durect.com.

NOTE: POSIMIR[®], SABER[®] and ORADUR[®] are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. POSIMIR, REMOXY ER and DUR-928 are investigational drugs under development and have not been approved for sale by the U.S. Food and Drug Administration or other health authorities.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/durect-to-present-at-the-rodman-renshaw-global-investment-conference-300322349.html

SOURCE DURECT Corporation

Matthew J. Hogan, Chief Financial Officer, DURECT, 408-777-4936